EXAGEN INC. Annual Report: A Clear View for Investors

This summary cuts through the jargon of EXAGEN INC.'s recent SEC 10-K filing to give you a straightforward look at its financial health and performance for the fiscal year ending December 31, 2025. Our goal is to provide retail investors with a clear understanding of the company's operations, financial standing, and future prospects.

1. Business Overview

EXAGEN INC. is a diagnostics company that develops and sells specialized tests for diagnosing and managing autoimmune diseases. Its flagship product, the AVISE CTD Test, is a blood test that helps doctors diagnose complex autoimmune conditions like lupus and rheumatoid arthritis, offering a more precise tool for patient care. In fiscal year 2025, the company continued to commercialization this key product and worked to strengthen its financial foundation.

2. Financial Performance

Financially, EXAGEN actively raised capital during the year. In May 2025, the company conducted a public offering of its common stock, selling new shares to investors to raise additional capital. It also maintained an "At-The-Market" (ATM) sales agreement, allowing it to sell shares directly into the market over time for flexible fundraising.

3. Management's Discussion and Analysis (MD&A) Highlights

Management's discussion focused on several key aspects of the company's operations and financial condition.

• Operational Focus: The company prioritized the commercialization and market penetration of its AVISE CTD Test, expanding its reach within the autoimmune diagnostics market.
• Capital Management: Management significantly focused on strengthening its capital structure. In April 2025, EXAGEN secured new financing through a "Perceptive Term Loan Facility" and concurrently amended an existing loan agreement with Innovatus Life Sciences Lending Fund. These actions, along with the successful public offering in May 2025, provided essential capital to fund ongoing operations, commercialization efforts, and strategic growth initiatives, and managed its debt profile.
• Strategic Initiatives: Management addressed how broader industry trends, such as advancements in autoimmune disease research and the evolving landscape of personalized medicine, impacted the company's strategy.

4. Financial Health, Liquidity, and Capital Structure

EXAGEN actively managed its financial health throughout the year. The company took on more debt through the Perceptive Term Loan Facility and issued warrants as part of the deal. Warrants give the holder the right to purchase company stock at a predetermined price, potentially leading to dilution for existing shareholders if exercised. The amendment of the Innovatus loan agreement also helped manage its debt profile. The capital raising activities during the year were crucial for maintaining liquidity and supporting operational needs.

As of June 30, 2025, EXAGEN's market capitalization was approximately $153.6 million. By March 6, 2026, the company had approximately 24 million shares outstanding. Its classification as a "Smaller reporting company" and "Non-accelerated filer" means it has a smaller market capitalization and revenue than larger public companies, often leading to fewer regulatory reporting requirements.

5. Risk Factors

Beyond concentration risks, the 10-K's "Risk Factors" section outlines potential threats that could significantly impact EXAGEN's business, financial condition, and results of operations. These typically include:

• Regulatory Risks: Difficulty obtaining or maintaining necessary regulatory approvals for diagnostic tests (e.g., FDA clearance) and complying with evolving healthcare regulations.
• Reimbursement Risks: Uncertainty or changes in healthcare reimbursement policies from government and private payers, which directly impact revenue and profitability.
• Competition: Intense competition from other diagnostic companies, pharmaceutical companies, and emerging technologies in the autoimmune disease market.
• Intellectual Property: Protecting proprietary technology, defending against infringement claims, and avoiding infringing on the intellectual property rights of others.
• Commercialization Challenges: Difficulties in market adoption, sales execution, scaling operations, and managing a growing sales force.
• Customer Concentration Risk: EXAGEN derives a substantial portion of its revenue from a limited number of key customers. The loss of any significant customer could materially impact financial results.
• Product Concentration Risk: The company's financial success heavily relies on the continued adoption and reimbursement of its primary product, the AVISE CTD Test. Any decrease in demand, increased competition, or adverse changes in reimbursement policies for this product could significantly affect revenue.
• Supplier Concentration Risk: EXAGEN depends on a few critical third-party suppliers for essential components and services. Disruptions in the supply chain or issues with these key suppliers could hinder operations and product availability.
• Cybersecurity Risks: The potential for data breaches or cyberattacks, which could compromise sensitive patient or company information, leading to reputational damage and financial losses.

6. Competitive Position

EXAGEN operates in a highly competitive autoimmune diagnostics market. The company primarily gains competitive advantages from its proprietary technology, the clinical validation and performance of the AVISE CTD Test, and its established commercial infrastructure. The market includes competitors who may offer alternative diagnostic solutions or have greater financial and marketing resources, making differentiation crucial for EXAGEN.

7. Future Outlook and Growth Strategy

Looking ahead, EXAGEN's management discussed its strategic priorities and anticipated milestones for the upcoming fiscal year. The company's financial activities in early 2026, including a "Tranche B loan" and additional warrants related to the Perceptive Term Loan Facility, suggests it continues to secure funding for future operations and growth.